FindTrial
Sign In

A randomised phase III study of intensive therapy with or without autologous bone marrow transplant (ABMT) in relapsed intermediate and high-grade non-hodgkin's lymphomas

A randomised phase III study of intensive therapy with or without autologous bone marrow transplant (ABMT) in relapsed intermediate and high-grade non-hodgkin's lymphomas

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN26449289
Enrollment
Unknown
Registered
2002-08-19
Start date
1990-01-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma (non-Hodgkin's) Cancer Lymphoma (non-Hodgkin's)

Interventions

Following registration all patients receive two courses of chemotherapy with dexamethasone, cisplatin and cytarabine (DHAP). Patients who meet all the eligibility criteria and who hav

Sponsors

Cancer Research UK (CRUK) (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged 16 to 60 years 2. Relapsed intermediate and high grade lymphoma 3. Patients must have previously been treated with an adriamycin-containing regimen or COM or COMLA 4. No central nervous system (CNS) or bone marrow involvement at relapse 5. Patients must have previously reached a first complete remission on induction regimen 6. Only first and second relapse patients are eligible

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026